Type 1 Diabetes Market Size, Share Global Analysis Report, 2020–2026

Industry Insights

[178+ Pages Report] According to the report published by Facts Factors, the global type 1 diabetes market size was worth around USD 2,000 million in 2019 and is predicted to grow to around USD 2,800 million by 2026 with a compound annual growth rate (CAGR) of roughly 5.0% between 2020 and 2026. The report analyzes the global type 1 diabetes market drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the type 1 diabetes market.

The type 1 diabetes market report analyzes and notifies the industry statistics at the global as well as regional and country levels in order to acquire a thorough perspective of the entire type 1 diabetes market. The historical and past insights are provided for FY 2016 to FY 2019 whereas projected trends are delivered for FY 2020 to FY 2026. The quantitative and numerical data is represented in terms of value (USD Million) from FY 2016 – 2026.

Key Insights from Primary Research

• Our primary respondents predict that the global type 1 diabetes market is expected to grow at a CAGR of nearly 5.0% over the projected period.
• The rising number of type 1 diabetes patients around the world has driven the consumption of insulin, which has driven the type 1 diabetes market.
• Our primary respondents also estimate that the global type 1 diabetes market in 2026 is expected to reach a market value of nearly USD 2,800 million.
• Asia Pacific market is anticipated to grow at the fastest rate over the projected period owing to the increasing population and rising number of type 1 diabetic patients.
• Emerging technologies in healthcare have led to the development of artificial pancreas is likely to create favorable conditions for new types of diabetic treatments.

Key Recommendations from Analysts

• Growing health awareness and increased healthcare spending has played a key role in the market growth.
• According to our analysts, the global type 1 diabetes market was valued at approximately USD 2,000 million in 2019.
• Based on geography, the North American segment held a share of nearly 35% in the global type 1 diabetes market in 2019.  
• Our analysts also predict that the emergence of gene consulting in predicting type 1 diabetes is likely to create new avenues for the global type 1 diabetes market.
• Lack of awareness and high cost of treatments such as insulin pump has restricted the type 1 diabetes market growth in developing and underdeveloped countries.

The quantitative data is further underlined and reinforced by comprehensive qualitative data which comprises various across-the-board market dynamics. The rationales which directly or indirectly impact the type 1 diabetes industry are exemplified through parameters such as growth drivers, restraints, challenges, and opportunities among other impacting factors.

Throughout our research report, we have encompassed all the proven models and tools of industry analysis and extensively illustrated all the key business strategies and business models adopted in the type 1 diabetes industry. The report provides an all-inclusive and detailed competitive landscape prevalent in the type 1 diabetes market.

The report utilizes established industry analysis tools and models such as Porter’s Five Forces framework to analyze and recognize critical business strategies adopted by various stakeholders involved in the entire value chain of the type 1 diabetes industry. The type 1 diabetes market report additionally employs SWOT analysis and PESTLE analysis models for further in-depth analysis.

The report study further includes an in-depth analysis of industry players' market shares and provides an overview of leading players' market position in the type 1 diabetes sector. Key strategic developments in the type 1 diabetes market competitive landscape such as acquisitions & mergers, inaugurations of different products and services, partnerships & joint ventures, MoU agreements, VC & funding activities, R&D activities, and geographic expansion among other noteworthy activities by key players of the type 1 diabetes market are appropriately highlighted in the report.

The type 1 diabetes market research report delivers an acute valuation and taxonomy of the type 1 diabetes industry by practically splitting the market on the basis of different types, categories, and regions. Through the analysis of the historical and projected trends, all the segments and sub-segments were evaluated through the bottom-up approach, and different market sizes have been projected for FY 2020 to FY 2026.

Report Scope

The regional segmentation of the type 1 diabetes industry includes the complete classification of all the major continents including North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Further, country-wise data for the type 1 diabetes industry is provided for the leading economies of the world.

Diabetes is a defect in metabolism in the pancreas that results in hyperglycemia. Type 1 diabetes also known as insulin-dependent diabetes mellitus or juvenile diabetes is a condition where there is an immune response against insulin-producing beta cells of the pancreas. In type 1 diabetes, there has to be an external supply of insulin hence called insulin-dependent diabetes mellitus. The most severe form of diabetes leads to the early destruction of organs. A person can prevent type 2 diabetes by avoiding sugar enrich food products in the diet, however, such prevention is not possible when it comes to type 1 diabetes. The immune system strikes colonies of cells in the body that would normally generate insulin, called islets, blocking or slowing down the insulin supply.

In recent years, there has been a steady rise in the number of type 1 diabetic patients. Type 1 diabetes is treated with injectable insulin and this type of insulin can't be treated with oral supplements. Injectable insulin uses an insulin pen to inject insulin under the skin. Type 1 diabetic patients have to mainly rely on injectable insulin. Such dependency of patients has driven the global type 1 diabetes insulin market.

The type 1 diabetes market is segmented based on drug type and region. On the basis of insulin analogs, the market is classified into rapid-acting insulin analogs, long-acting insulin analogs, and premix insulin analogs.

Some of the essential players operating in the type 1 diabetes market, but not restricted to include

• Eli Lilly and Company
• Bayer Pharmaceuticals
• Sanofi
• Novo Nordisk
• AstraZeneca PLC.
• XOMA Corp.
• DiaVacs Inc.
• B.BraunMelsungen AG
• Biodel Inc.
• Macrogenics Inc.
• Takeda Pharmaceutical

The taxonomy of the type 1 diabetes industry by its scope and segmentation is as follows:

By Insulin Analog Segmentation Analysis

• Rapid-Acting Insulin Analogs
• Long-Acting Insulin Analogs
• Premix Insulin Analogs

Regional Segmentation Analysis

• North America
  • The U.S.
  • Canada
• Europe
  • Germany
  • The UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa